(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of -16.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.71%.
Immatics Nv's revenue in 2025 is $169,385,869.On average, 2 Wall Street analysts forecast IMTX's revenue for 2025 to be $7,229,804,052, with the lowest IMTX revenue forecast at $6,586,803,658, and the highest IMTX revenue forecast at $7,872,804,446. On average, 2 Wall Street analysts forecast IMTX's revenue for 2026 to be $7,229,804,052, with the lowest IMTX revenue forecast at $6,586,803,658, and the highest IMTX revenue forecast at $7,872,804,446.
In 2027, IMTX is forecast to generate $13,895,615,320 in revenue, with the lowest revenue forecast at $13,895,615,320 and the highest revenue forecast at $13,895,615,320.